Azienda Ospedaliera Universitaria Di Cagliari
- Address
- lock Available on a paid plan
Oncology Research
At Azienda Ospedaliera Universitaria Di Cagliari, the main focus in oncology is advanced colorectal cancer, with a strong emphasis on patients carrying the KRAS G12C mutation. These studies are designed to assess whether new treatment combinations can improve disease control and offer better options after standard therapy.
- Advanced colorectal cancer with KRAS G12C mutation
- Testing new treatment strategies for patients whose disease has progressed after first-line care
- Comparing targeted therapy combinations with standard chemotherapy
This research helps evaluate whether more precise cancer treatments can improve outcomes for people with difficult-to-treat neoplasms.
Respiratory Disease Studies
The site also conducts clinical research in respiratory tract diseases, especially severe asthma with an eosinophilic phenotype. These trials aim to better understand long-term safety and support more effective control of persistent asthma symptoms in patients already receiving standard care.
- Severe asthma with an eosinophilic phenotype
- Evaluating long-term safety of new add-on treatment options
- Improving management for patients with difficult-to-control asthma
Overall, the respiratory studies are focused on expanding treatment choices and improving the quality of life for people living with chronic asthma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 122 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 113 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Universitaria Di Cagliari
lock Showing 1 of 84 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial | Fondazione GONO G.I. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 122 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 11 | Unknown | 2020-10-22 | 2025-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.